We are live on ! Find out more
JAM

JW Asset Management Portfolio holdings

AUM $244M
1-Year Est. Return 71.51%
This Fund
S&P 500
This Quarter Est. Return
+41.12%
1 Year Est. Return
+71.51%
3 Year Est. Return
+125.61%
5 Year Est. Return
+131.61%
10 Year Est. Return
+2,490.27%
AUM
$195M
AUM Growth
+$59M
Cap. Flow
+$9.73M
Cap. Flow %
5%
Top 10 Hldgs %
94.35%
Holding
19
New
2
Increased
–
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
CTST
CannTrust Holdings Inc. Common Share
CTST
+$12.7M
2
HEXO
HEXO Corp. Common Shares
HEXO
+$86.8K

Top Sells

Rank Stock Value
1
LGND icon
Ligand Pharmaceuticals
LGND
+$1.82M
2
ACB
Aurora Cannabis
ACB
+$1.28M

Sector Composition

Rank Sector Weight
1 Healthcare 79.44%
2 Consumer Discretionary 17.95%
3 Technology 2.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGC
1
Canopy Growth
CGC
$377M
$55.9M 28.71%
129,120
– –
AMZN icon
2
Amazon
AMZN
$2.48T
$35M 17.95%
392,540
– –
EGRX
3
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$21.5M 11.04%
425,755
– –
CRON
4
Cronos Group
CRON
$1.06B
$19.9M 10.23%
1,081,444
– –
ACB
5
Aurora Cannabis
ACB
$168M
$18M 9.26%
16,605
-1,430
-8% -$1.28M
CTST
6
DELISTED
CannTrust Holdings Inc. Common Share
CTST
$10.9M 5.58%
+1,399,909
New +$12.7M
HZNP
7
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$7.16M 3.67%
270,775
– –
ATRS
8
DELISTED
Antares Pharma, Inc.
ATRS
$5.82M 2.99%
1,920,524
– –
MSFT icon
9
Microsoft
MSFT
$2.92T
$4.89M 2.51%
41,500
– –
PETQ
10
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
$4.68M 2.4%
148,855
– –
BSTC
11
DELISTED
BioSpecifics Technologies Corp.
BSTC
$4.59M 2.36%
73,649
– –
ESTA icon
12
Establishment Labs
ESTA
$2.7B
$3.85M 1.97%
160,000
– –
RVLP
13
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
$810K 0.42%
225,000
– –
AVDL
14
DELISTED
Avadel Pharmaceuticals
AVDL
$640K 0.33%
444,439
– –
ALIM
15
DELISTED
Alimera Sciences
ALIM
$438K 0.22%
27,553
– –
NVLN
16
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$389K 0.2%
315,979
– –
APHA
17
DELISTED
Aphria Inc. Common Shares
APHA
$192K 0.1%
20,636
– –
HEXO
18
DELISTED
HEXO Corp. Common Shares
HEXO
$99K 0.05%
+268
New +$86.8K
LGND icon
19
Ligand Pharmaceuticals
LGND
$5.94B
– –
-21,482
Closed -$1.82M

Similar funds

SC
Schulhoff & Co Cincinnati, Ohio $243M AUM 17.47% 1-Year Est. Return
HCM
Hutner Capital Management Manchester, Vermont $243M AUM 10.01% 1-Year Est. Return
SC
Solstein Capital Menlo Park, California $244M AUM 29.05% 1-Year Est. Return
HBS
Howard Bailey Securities Fort Wayne, Indiana $243M AUM 13.36% 1-Year Est. Return
GIM
GE Investment Management Norwalk, Connecticut $244M AUM 41.62% 1-Year Est. Return
IFO
Independent Family Office Albany, New York $243M AUM 21.81% 1-Year Est. Return
VG
Visualize Group New York $243M AUM 6.21% 1-Year Est. Return
CP
Creekside Partners Petaluma, California $243M AUM 20.23% 1-Year Est. Return

JW Asset Management's Q1 2019 Portfolio in Review

As of Q1 2019, JW Asset Management held 19 positions worth $195M, up 43% from $136M the previous quarter. Its ten largest holdings account for 94% of the portfolio.

JW Asset Management deployed $9.73M of net new capital in Q1 2019, opening 2 new positions. Its largest new stake was CannTrust Holdings Inc. Common Share: 1,399,909 shares worth $10.9M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 75% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was Aurora Cannabis, an estimated $1.28M trimmed.

  • JW Asset Management's largest Q1 2019 buy was CannTrust Holdings Inc. Common Share: 1,399,909 shares worth $10.9M.
  • JW Asset Management's biggest Q1 2019 reduction was Aurora Cannabis, cutting an estimated $1.28M.
  • JW Asset Management fully exited Ligand Pharmaceuticals in Q1 2019, selling an estimated $1.82M.
  • JW Asset Management's ten largest holdings make up 94% of its $195M portfolio in Q1 2019.
  • JW Asset Management opened 2 new positions and closed 1 in Q1 2019.
  • JW Asset Management's portfolio value rose 43% quarter-over-quarter to $195M.

Based on JW Asset Management's 13F filing for Q1 2019, filed 14 May 2019.